key: cord-0306784-t7wp0ewe
authors: Jethani, N.; Zhang, H.; Chinitz, L.; Aphinyanaphongs, Y.; Ranganath, R.; Jankelson, L.
title: QTNet: Predicting Drug-Induced QT prolongation with Deep Neural Networks
date: 2021-03-26
journal: nan
DOI: 10.1101/2021.03.24.21254235
sha: 417c7753f351e555d8801a3c0e60ba3ba40fec0a
doc_id: 306784
cord_uid: t7wp0ewe

Background:Drug-induced QTc prolongation (diQTP) is frequent and associated with a risk of sudden cardiac death. Identifying patients at risk of diQTP can enhance monitoring and treatment plans. Objective: To develop a machine learning architecture for prediction of extreme diQTP (QTc >500ms OR {Delta}QTc >60ms) at the onset of treatment with a QTc prolonging drug. Methods: We included 4,628 adult patients who received a baseline ECG within 6 months prior to treatment onset with a QTc prolonging drug and a follow-up ECG after the fifth dose. We collected known clinical QTc prolongation risk factors (CF). We developed a novel neural network architecture (QTNet) to predict diQTP from both the CF and baseline ECG data (ECGD), composed of both the ECG waveform and measurements (i.e. QTc),by fusing a state-of-the-art convolution neural network to process raw ECG waveforms with the CF using amulti-layer perceptron. We fit a logistic regression model using the CF, replicating RISQ-PATH as Baseline. We further compared the performance of QTNet (CF+ECGD) to neural network models trained using three variable subsets: a) baseline QTc (QTC-NN), b) CF-NN, and c) ECGD-NN. Results: diQTP was present in 1030 patients (22.3%), of which baseline QTc was normal (QTc<450ms:Male/<470ms:Female) in 405 patients (39.3%). QTNet achieved the best performance (Figure 1)(AUROC, 0.802 [95% CI, 0.782-0.820]), outperforming predictions based on the Baseline (AUROC, 0.738 [95%CI, 0.716-0.757]), QTC-NN (AUROC, 0.735 [95% CI, 0.710-0.757]), CF-NN (AUROC, 0.778 [95% CI, 0.757-0.799]), and ECGD-NN (AUROC, 0.774 [95% CI, 0.750-0.794]). Conclusion: We developed QTNet, the first deep learning model for predicting extreme diQTP, outperforming models trained on known clinical risk factors.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ;

Drug-induced QTc prolongation (diQTP) is associated with increased risk of Torsades de Pointes and sudden cardiac death. Recently, widespread use of hydroxychloroquine as a treatment for COVID-19 put many patients at risk of these adverse events. Many more drugs are known to induce QTc prolongation, as listed by Crediblemeds 1 . We developed QTNet, a novel machine learning architecture which uses raw ECG waveforms, to predict the risk of developing QTc prolongation upon treatment onset with a QTc prolonging drug.

We identified adults aged ≥18 years who were administered a QTc prolonging drug while admitted to New York University Langone Health between January 1, 2013 and January 13, 2021. A subset of the QT-prolonging medications with known risk for TdP, as defined by CredibleMeds 1 , were selected on the basis of administration frequency and expert opinion. This subset included Fluconazole, Hydroxychloroquine, Amiodarone, Donepezil, Escitalopram, Levofloxacin, Citalopram, Erythromycin, Ciprofloxacin, Haloperidol, and Dronedarone. Patients were eligible for inclusion if at least five doses of a QTc prolonging drug were administered, a "reference" 10s, 12 lead ECG was recorded within 6 months prior to the onset of treatment, and a "follow-up" ECG was recorded after the fifth dose and prior to drug cessation. Patients were split into training, validation, and test datasets in a 3:1:1 ratio.

Reference ECG data (ECGD) consisted of both the raw waveform and MUSE calculated measurements (i.e. PR interval). The corrected QT-interval (QTc) was calculated using the Bazett method. Extreme QTc prolongation, defined as QTc ≥500ms or ∆QTc≥60ms, present in any follow-up ECG was used as the study endpoint.

We collected known clinical QTc prolongation risk factors (CF) as identified in the RISQ-PATH 2 model, which included patient demographics, laboratory values, vital signs, past medical history, and medication history as well the reference QTc measurement. Missingness indicators were included for each variable.

We developed a novel neural network architecture (QTNet) to predict diQTP from both the CF and ECGD, by fusing a state-of-the-art convolution neural network 3 to process raw ECG waveforms with the CF using a fully-connected neural network. We tuned both the number of layers (1,2, or 3) and hidden dimension size (100, 1000, or 10000) of the multi-layer perceptron.

Applying the previously published RISQ-PATH model directly to our data performed poorly (AUROC, 0.537 [95% CI, 0.510-0.563]), therefore we refit a logistic regression model using the CF, replicating RISQ-PATH as Baseline. We also evaluated the use of the reference QTc (QTC) exclusively as a risk score.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.24.21254235 doi: medRxiv preprint

QTdrugs List. www.crediblemeds.org

A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model

Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network

Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes